I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EHA 2024

-
Coming soon
07:00 AM
Duration 1hr Madrid, Spain
Glofitamab▼ monotherapy retreatment in patients with heavily pre-treated relapsed or refractory Non-Hodgkin lymphoma (NHL): results from a phase I/II study
Bachy E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 PM
Duration 1hr Madrid, Spain
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2, and 3 and COMPOSER trials of patients with paroxysmal nocturnal hemoglobinuria (PNH)
Fu R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Madrid, Spain
Phase III COMMODORE 1 and COMMODORE 2 trials: treatment satisfaction and preference in patients with paroxysmal nocturnal hemoglobinuria (PHN) treated with crovalimab and eculizumab or ravulizumab
Kulasekararaj A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Madrid, Spain
Response in molecular subgroups and circulating tumor (CT)DNA kinetics in patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) treated with glofitamab▼ monotherapy
Carlo-Stella C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Madrid, Spain
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the Phase III Pola▼-R-CHP vs R-CHOP (POLARIX) study
Salles G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Madrid, Spain
Treatment effectiveness of venetoclax in combination with hypomethylating agents in patient subgroups with acute myeloid leukemia: experience from routine clinical practices in the United States
Bachiashvili K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:45 PM
Duration 90mins Hall Picasso
Glofitamab▼ plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)
Abramson J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:30 PM
Duration 75mins Hall Dali 2
Glofitamab▼ monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: updated analysis from a phase I/II study
Phillips T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 75mins Hall Dali 2
Mosunetuzumab▼ demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study
Assouline S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:30 AM
Duration 75mins Hall Picasso
Cevostomab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: initial results from the Phase I/II CAMMA 2 study
Kumar S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar